Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Trial ID or NCT#
NCT02032823
Status
NOT RECRUITING
Purpose
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Official Title
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Eligibility Criteria
Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Allison W. Kurian, M.D., M.Sc.
Medical oncologist,
Breast specialist,
Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Douglas W. Blayney
Contact us to find out if this trial is right for you.
Contact
CCTO
650-498-7061
View on ClinicalTrials.gov
